GH Receptor Antagonists: Basic Knowledge and Clinical Perspectives

  • A. J. van der Lely
Conference paper


GH is a protein that contains 191 amino acids with two disulfide bonds and four a helices (Abdel-Meguid et al., 1987; de Vos et al., 1992). Its molecular mass is approximately 22 kDa. GH is secreted by the anterior pituitary gland (Theill and Karin, 1993; Ohlsson et al., 1998). GH signal transduction begins with GH binding to a transmembrane GH receptor (Lesniak et al., 1973). GH has two distinct binding domains that bind to two identical GHRs at the cell surface. The initial (high-affinity) binding of the GH binding site I at the GHR is followed by binding at the GH site II, which produces functional receptor dimerization of the two GHRs (de Vos et al., 1992; Carter-Su et al., 2000).


Growth Hormone Growth Hormone Receptor Active Acromegaly Growth Hormone Binding Growth Hormone Receptor Antagonist 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abdel-Meguid S.S., Shieh H.S., Smith W.W., Dayringer H.E., Violand B.N. and Bentie L.A. (1987). Three-dimensional structure of a genetically engineered variant of porcine growth hormone. Proc Natl Acad Sci USA 84, 6434–6437.PubMedCrossRefGoogle Scholar
  2. Bellush L.L., Doublier S., Holland A.N., Striker L.J., Striker G.E. and Kopchick J.J. (2000). Protection against diabetes-induced nephropathy in growth hormone receptor/binding protein gene-disrupted mice. Endocrinology, 141, 163–168.PubMedCrossRefGoogle Scholar
  3. Carter-Su C, Rui L. and Herrington J. (2000). Role of the tyrosine kinase JAK2 in signal transduction by growth hormone. Pediatr Nephrol, 14, 550–557.PubMedCrossRefGoogle Scholar
  4. Chan J.M., Stampfer M.J., Giovannucci E., Gann P.H., Ma J., Wilkinson P., Hennekens C.H. and Pollak M. (1998). Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science, 279, 563–566.PubMedCrossRefGoogle Scholar
  5. Chen N.Y., Chen W.Y., Bellush L., Yang C.W., Striker L.J., Striker G.E. and Kopchick J.J. (1995). Effects of streptozotocin treatment in growth hormone (GH) and GH antagonist transgenic mice. Endocrinology, 136, 660–667.PubMedCrossRefGoogle Scholar
  6. Chen N.Y., Chen W.Y. and Kopchick J.J. (1996). A growth hormone antagonist protects mice against streptozotocin induced glomerulosclerosis even in the presence of elevated levels of glucose and glycated hemoglobin. Endocrinology, 137, 5163–5165.PubMedCrossRefGoogle Scholar
  7. Chen W.Y., Chen N., Yun J., Wagner T.E. and Kopchick J.J. (1994). In vitro and in vivo studies of the antagonistic effects of human growth hormone analogs. J Biol Chem, 269, 20806.PubMedGoogle Scholar
  8. Chen W.Y., White M.E., Wagner T.E. and Kopchick J.J. (1991a). Functional antagonism between endogenous mouse growth hormone (GH) and a GH analog results in dwarf transgenic mice. Endocrinology, 129, 1402–1408.CrossRefGoogle Scholar
  9. Chen W.Y., Wight D.C., Mehta B.V., Wagner T.E. and Kopchick J.J. (1991b). Glycine 119 of bovine growth hormone is critical for growth-promoting activity. Mol Endocrinol, 5, 1845–1852.CrossRefGoogle Scholar
  10. Chen W.Y., Wight D.C., Wagner T.E. and Kopchick J.J. (1990). Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice. Proc Nat Acad Sci USA, 87, 5061–5065.PubMedCrossRefGoogle Scholar
  11. de Vos A.M., Ultsch M. and Kossiakoff A.A. (1992). Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science, 255, 306–312.PubMedCrossRefGoogle Scholar
  12. Duan H., Dagnaes-Hansen R, Rasmussen L., Friend K.E., Orskov H., Bennet W.F. and Flyvbjerg A. (1999). GH receptor antagonist treatment inhibits growth of human colorectal carcinoma, COLO205 in nude mice. Program of the 5th International Symposium on Insulin-like Growth Factors, Brighton, 1999 (Abstract P13).Google Scholar
  13. Flyvbjerg A., Bennett W.F., Rasch R., Kopchick J.J. and Scarlett J.A. (1999). Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy, and urinary albumin excretion in experimental diabetes in mice. Diabetes, 48, 377–382.PubMedCrossRefGoogle Scholar
  14. Friend K.E. (2000). Targeting the growth hormone axis as a therapeutic strategy in oncology. Growth Horm IGF Res, 10 (suppl A), S45–S46.PubMedCrossRefGoogle Scholar
  15. Friend K.E., Flyvbjerg A., Bennet W.F. and McCutcheon I.E. (2000). The growth hormone receptor antagonist pegvisomant exhibits antitumor activity in multiple preclinical tumor models. Proceedings of the 11th NCI-EORTC-AACR Symposium, Amsterdam, The Netherlands (Abstract 420).Google Scholar
  16. Friend K.E., Radinsky R. and McCutcheon I.E. (1999). Growth hormone receptor expression and function in meningiomas: effect of a specific receptor antagonist. J Neurosurg, 91, 93–99.PubMedCrossRefGoogle Scholar
  17. Fuh G., Cunningham B.C., Fukunaga R., Nagata S., Goeddel D.V. and Wells J.A. (1992). Rational design of potent antagonists to the human growth hormone receptor. Science, 256, 1677–1680.PubMedCrossRefGoogle Scholar
  18. Growth Hormone Antagonist for Proliferative Diabetic Retinopathy Study Group (2001). The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy. Ophthalmology, 108, 2266–2272.CrossRefGoogle Scholar
  19. Hankinson S.E., Willett W.C., Colditz G.A., Hunter DJ., Michaud D.S., Deroo B., Rosner B., Speizer RE. and Pollak M. (1998). Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet, 351, 1393–1396.PubMedCrossRefGoogle Scholar
  20. Hansen A.P. and Johansen K. (1970). Diurnal patterns of blood glucose, serum free fatty acids, insulin, glucagon and growth hormone in normals and juvenile diabetics. Diabetologia, 6, 27–33.PubMedCrossRefGoogle Scholar
  21. Herman-Bonert V.S., Zib K., Scarlett J.A. and Melmed S. (2000). Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. J Clin Endocrinol Metab, 85, 2958–2961.PubMedCrossRefGoogle Scholar
  22. Ho K.K. (2001). Place of pegvisomant in acromegaly. Lancet, 358, 1743–1744.PubMedCrossRefGoogle Scholar
  23. Khandwala H.M., McCutcheon I.E., Flyvbjerg A. and Friend K.E. (2000). The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev, 21, 215–244.PubMedCrossRefGoogle Scholar
  24. Lesniak M.A., Roth J., Görden P. and Gavin J.R. III (1973). Human growth hormone radioreceptor assay using cultured human lymphocytes. Nature New Biol, 241, 20–22.PubMedGoogle Scholar
  25. Lundbaek K., Jensen V.A., Olsen TS., Orskov H., Christensen N.J., Johansen K., Hansen A.P. and Osterby R. (1970). Growth hormone and diabetic angiopathy. Lancet, 2, 472.PubMedGoogle Scholar
  26. Ma J., Pollak M.N., Giovannucci E., Chan J.M., Tao Y., Hennekens CH. and Stampfer M.J. (1999). Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst, 91, 620–625.PubMedCrossRefGoogle Scholar
  27. McCutcheon I.E., Flyvbjerg A., Hill H., Li J., Bennett W.F., Scarlett J.A. and Friend K.E. (2001). Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J Neurosurg, 94, 487–492.PubMedCrossRefGoogle Scholar
  28. Melmed S. (1990). Acromegaly. N Engl J Med, 322, 966–977.PubMedCrossRefGoogle Scholar
  29. Melmed S. (2001). Acromegaly and cancer: not a problem? J Clin Endocrinol Metab, 86, 2929–2934.PubMedCrossRefGoogle Scholar
  30. O’Dell S.D. and Day I.N. (1998). Insulin-like growth factor II (IGF-II). Int J Biochem Cell  Biol, 30, 767–771.PubMedCrossRefGoogle Scholar
  31. Ohlsson C, Bengtsson B.A., Isaksson O.G., Andreassen TT and Slootweg M.C. (1998). Growth hormone and bone. Endocr Rev, 19, 55–79.PubMedCrossRefGoogle Scholar
  32. Orme S.M., McNally R.J., Cartwright R.A. and Belchetz P.E. (1998). Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab, 83, 2730–2734.PubMedCrossRefGoogle Scholar
  33. Osborne C.K., Clemmons D.R. and Arteaga CL. (1990). Regulation of breast cancer growth by insulin-like growth factors. J Steroid Biochem Mol Biol, 37, 805–809.PubMedCrossRefGoogle Scholar
  34. Pollak M., Blouin M.J., Zhang J.C and Kopchick J.J. (2001). Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist. Br J Cancer, 85, 428–430.PubMedCrossRefGoogle Scholar
  35. Rodvold K. A. and van der Lely A. J. (1999). Pharmacokinetics and pharmacodynamics of B2036PEG, a novel growth hormone receptor antagonist, in acromegalic subjects. The Endocrine Society 81st Annual Meeting. June 12–15 1999, San Diego, CA, Abstract P1-049.Google Scholar
  36. Segev Y., Landau D., Rasch R., Flyvbjerg A. and Phillip M. (1999). Growth hormone receptor antagonism prevents early renal changes in nonobese diabetic mice. J Am Soc Nephrol, 10, 2374–2381.PubMedGoogle Scholar
  37. Smith L.E., Kopchick J.J., Chen W., Knapp J., Kinose E, Daley D., Foley E., Smith R.G. and Schaeffer J.M. (1997). Essential role of growth hormone in ischemia-induced retinal neovascularization. Science, 276, 1706–1709.PubMedCrossRefGoogle Scholar
  38. Theill L.E. and Karin M. (1993). Transcriptional control of GH expression and anterior pituitary development. Endocr Rev,14, 670–689.PubMedGoogle Scholar
  39. Thorner M.O., Strasburger C.J.,Wu Z., Straume M., Bidlingmaier M., Pezzoli S.S., Zib K., Scarlett J.C. and Bennett W.E. (1999). Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036- PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. J Clin Endocrinol Metab, 84, 2098–2103.PubMedCrossRefGoogle Scholar
  40. Trainer P.J., Drake W.M., Katznelson L., Freda P.U., Herman-Bonert V., van der Lely A.J., Dimaraki E.V., Stewart P.M., Friend K.E., Vance M.L., Besser G.M., Scarlett J.A., Thorner M.O., Parkinson C., Klibanski A., Powell J.S., Barkan A.L., Sheppard M.C., Malsonado M., Rose D.R., Clemmons D.R., Iohannsson G., Bengtsson B.A., Stavrou S., Kleinberg D.L., Cook D.M., Phillips L.S., Bidlingmaier M., Strasburger C.T., Hackett S., Zib K., Bennett W.E and Davis R.J. (2000). Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med, 342, 1171–1177.PubMedCrossRefGoogle Scholar
  41. Utiger R.D. (2000). Treatment of acromegaly. N Engl J Med, 342, 1210–1211.PubMedCrossRefGoogle Scholar
  42. van der Lely A.J., Hutson R.K., Trainer P.J., Besser G.M., Barkan A.L., Katznelson L., Klibanski A., Herman-Bonert V., Melmed S., Vance M.L., Freda P.U., Stewart P.M., Friend K.E., Clemmons D.R., Johannsson G., Stavrou S., Cook D.M., Phillips L.S., Strasburger C.J., Hackett S., Zib K.A., Davis R.J., Scarlett J.A. and Thorner M.O. (2001a). Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet, 358, 1754–1759.CrossRefGoogle Scholar
  43. van der Lely A.J., Muller A., Janssen J.A., Davis R.J., Zib K.A., Scarlett J.A. and Lamberts S.W. (2001b). Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. J Clin Endocrinol Metab, 86, 478–481.CrossRefGoogle Scholar
  44. Veldhuis J.D., Bidlingmaier M., Wu Z. and Strasburger C.J. (2000). A selective recombinant human (rh) GH-receptor antagonist fails to impede metabolic removal of endogenous or exogenous GH in healthy adults: evidence that the GH receptor does not participate primarily in the in vivo GH elimination process. 11th International Congress of Endocrinology 2000, Sydney, Australia, p. 405.Google Scholar
  45. Yde H. (1969). Abnormal growth hormone response to ingestion of glucose in juvenile diabetics. Acta Med Scand, 186, 499–504.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2003

Authors and Affiliations

  • A. J. van der Lely

There are no affiliations available

Personalised recommendations